Summary:
An interventional phase 2/3, adaptive, multi-center, randomized, double-blind study to investigate efficacy and safety of oral sisunatovir compared with placebo in non- hospitalized symptomatic adults with respiratory syncytial virus infection who are at risk of progression to severe illness.